ARIAD Pharmaceuticals, Inc. (Nasdaq: ARIA) today announced that the U.S. District Court for the District of Delaware granted ARIAD's motion to permit an immediate appeal of the Court's summary judgment ruling of non-infringement by Amgen's drug, Enbrel(R) (etanercept), of seven claims of U.S. Patent No. 6,410,516 (the '516 patent). The Court also cancelled the trial scheduled for November 2008 and administratively closed the case at this time.
The details can be read here.
No comments:
Post a Comment